EXPRESSF+
LIVE

Serial Number

75684834

Owner

PROTEIN SCIENCES CORPORATION

Attorney

Karen Lim

First Use Date

Apr 7, 1999

Filing Date

Apr 19, 1999

Add to watchlist:

No watchlists yet
View on USPTO

EXPRESSF+ Trademark

Serial Number: 75684834 • Registration: 2359863

EXPRESSF+ is a trademark filed by PROTEIN SCIENCES CORPORATION on April 19, 1999. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

PROTEIN SCIENCES CORPORATION (29 trademarks)

MERIDEN, CT 06450

Entity Type: 03

Trademark Details

Filing Date

April 19, 1999

Registration Date

June 20, 2000

First Use Anywhere

April 7, 1999

First Use in Commerce

April 7, 1999

Published for Opposition

March 28, 2000

Goods & Services

Cell lines for use in the production of recombinant proteins for scientific, laboratory and medical research and cells for research of a scientific, laboratory or medical nature, including an insect line, a baculovirus-suspectible insect cell line, and a spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent Sf9 cells, cells which replicate in serum-free medium, cells which grow as a suspension of single cells without significant clumping, cells which grow exponentially with a cell doubling time of 18 to 24 hours, cells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%), cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stocks, cells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectors, cells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agencies, and cells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards

Cell lines for use in the production of recombinant proteins for medical and clinical use and cells for medical or clinical use, including an insect line, a baculovirus-suspectible insect cell line, and a spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent of Sf9 cells, cells which replicate in serum-free medium, cells which grow as a suspension of single cells without significant clumping, cells which grow exponentially with a cell doubling time of 18 to 24 hours, cells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%), cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stocks, cells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectors, cells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agencies, and cells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Dec 16, 2021 NA89
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 16, 2021 APRE
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Dec 16, 2021 RNL2
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Dec 16, 2021 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 5, 2021 APRE
PETITION TO DIRECTOR GRANTED
Dec 3, 2021 PCGR
ASSIGNED TO PETITION STAFF
Nov 30, 2021 APET
TEAS PETITION TO DIRECTOR RECEIVED
Apr 21, 2021 TPDR
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Apr 1, 2021 PR89
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Jan 25, 2021 EROP
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Oct 15, 2020 PR89
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 30, 2020 APRE
TEAS SECTION 8 & 9 RECEIVED
Aug 20, 2020 E89R
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
Jan 8, 2020 CORV
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 10, 2019 CRFA
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 20, 2019 REM2
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Sep 19, 2018 ASCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 4, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 4, 2018 REAP
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Aug 2, 2017 ASCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 11, 2010 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 11, 2010 REAP
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
May 21, 2010 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
May 21, 2010 89AG
TEAS SECTION 8 & 9 RECEIVED
May 18, 2010 E89R
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 1, 2007 C15A
ASSIGNED TO PARALEGAL
Feb 20, 2007 PLGL
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Dec 19, 2006 815F
TEAS SECTION 8 & 15 RECEIVED
Dec 19, 2006 E815
CASE FILE IN TICRS
Mar 23, 2006 CFIT
REGISTERED-PRINCIPAL REGISTER
Jun 20, 2000 R.PR
PUBLISHED FOR OPPOSITION
Mar 28, 2000 PUBO
NOTICE OF PUBLICATION
Feb 25, 2000 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 28, 2000 CNSA
USE AMENDMENT ACCEPTED
Jan 28, 2000 IUAA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 18, 1999 CRFA
NON-FINAL ACTION MAILED
Sep 16, 1999 CNRT
ASSIGNED TO EXAMINER
Sep 3, 1999 DOCK
ASSIGNED TO EXAMINER
Aug 20, 1999 DOCK
AMENDMENT TO USE PROCESSING COMPLETE
Jul 30, 1999 AUPC
USE AMENDMENT FILED
Jun 30, 1999 IUAF